Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 4Active not recruiting 3Completed 2Withdrawn 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Non-Hodgkin 3Lymphoma, B-Cell 3Lymphoma 2Lymphoma, Follicular 1Burkitt Lymphoma 1

Interventions

Rituximab 16Cyclophosphamide 16Prednisone 7Doxorubicin 7pirtobrutinib 6fludarabine 6Vincristine 6Lenalidomide 6venetoclax 5pembrolizumab 5fludarabine phosphate 5Etoposide 5Bendamustine Hydrochloride 5ibrutinib 4acalabrutinib 4Specimen Handling 4Magnetic Resonance Spectroscopy 4Dexamethasone 4CT-P10 4polatuzumab vedotin 3etoposide phosphate 3Immunotherapy, Adoptive 3tazemetostat 2liposomal doxorubicin 2Nivolumab 2Injections 2Ifosfamide 2Gemcitabine 2Cisplatin 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, B-Cell × polatuzumab vedotin × Clear all
NCT04594798 2025-12-17

A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL

University of Rochester

Phase 2 Active not recruiting
39 enrolled
Lymphoid

Lymphoma, B-Cell

NCT05410418 2025-12-15

Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma

Washington University School of Medicine

Phase 2 Active not recruiting
34 enrolled
Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell

NCT03671018 2024-11-29

A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

Hoffmann-La Roche

Phase 1/2 Active not recruiting
422 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡